XOMA Co. (NASDAQ:XOMA) Expected to Earn Q1 2024 Earnings of ($0.85) Per Share

XOMA Co. (NASDAQ:XOMA) – Stock analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for XOMA in a research report issued on Monday, April 29th. Leerink Partnrs analyst D. Risinger forecasts that the biotechnology company will post earnings of ($0.85) per share for the quarter. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for XOMA’s current full-year earnings is ($1.73) per share. Leerink Partnrs also issued estimates for XOMA’s Q2 2024 earnings at ($0.79) EPS, Q3 2024 earnings at ($0.54) EPS, Q4 2024 earnings at ($0.69) EPS, FY2024 earnings at ($2.87) EPS, FY2025 earnings at ($1.63) EPS, FY2026 earnings at ($0.37) EPS, FY2027 earnings at $1.05 EPS and FY2028 earnings at $3.31 EPS.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.13). XOMA had a negative net margin of 886.91% and a negative return on equity of 25.17%. The firm had revenue of $1.83 million for the quarter, compared to analyst estimates of $1.01 million.

Other equities analysts also recently issued research reports about the stock. SVB Leerink started coverage on shares of XOMA in a report on Monday. They set an “outperform” rating and a $40.00 price target for the company. HC Wainwright restated a “buy” rating and set a $74.00 price objective on shares of XOMA in a research note on Wednesday.

XOMA Stock Performance

Shares of XOMA opened at $25.44 on Thursday. XOMA has a 1 year low of $13.48 and a 1 year high of $27.00. The company has a market cap of $296.12 million, a price-to-earnings ratio of -6.30 and a beta of 0.57. The company has a debt-to-equity ratio of 1.34, a quick ratio of 8.68 and a current ratio of 8.68. The firm has a fifty day moving average of $25.10 and a 200-day moving average of $20.71.

Institutional Investors Weigh In On XOMA

A hedge fund recently raised its stake in XOMA stock. BNP Paribas Financial Markets lifted its stake in shares of XOMA Co. (NASDAQ:XOMA) by 55.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,543 shares of the biotechnology company’s stock after purchasing an additional 1,266 shares during the quarter. BNP Paribas Financial Markets’ holdings in XOMA were worth $85,000 at the end of the most recent reporting period. 95.92% of the stock is currently owned by institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.